Delix Therapeutics

Meet Retsina Meyer, PhD, Head of Corporate Strategy at Delix Therapeutics!  Whether it is working to help drive our strategic imperatives, navigating business development efforts, or engaging with potential partners, Retsina works closely with #TeamDelix to tackle complex challenges and foster growth in #brainhealth. Her leadership supports the teams across Delix in advancing #CNS treatments and developing novel #neuroplasticity therapies that are shaping the future of patient care.  We’re grateful for Retsina’s expertise and commitment to the Delix team and patients in support of transforming lives through cutting-edge solutions and groundbreaking treatments for those who need them most. 

Join Delix Therapeutics CEO, Mark Rus, at the Longwood Healthcare Leaders CEO event in Boston, MA on October 28–29, where he and fellow CEO panelists will speak on ‘Identifying Next Generation Therapeutics’. Hear about Delix's innovative pipeline of rapid-acting #neuroplastogens for a broad range of significant unmet needs in neuropsychiatry, neurology, and beyond.  For this panel and more, register here: https://lnkd.in/dJ_8trZM.   Cc Rosana Kapeller from ROME Therapeutics, Oliver Rosen from Akamis Bio, Paul Peter Tak, MD PhD FMedSci from Candel Therapeutics, and Brian Taylor from SmartLabs #longwoodhealthcareleaders #NextGenTherapeutics

🌍 A recent study in The Lancet Psychiatry revealed that 1 in 2 people worldwide will develop a mental health disorder during their lifetime. 🧠 With up to 46% of depression patients not fully responding to traditional antidepressants (National Institutes of Health), the need for new treatments is more critical than ever. This #WorldMentalHealthDay, Cumulus Neuroscience is proud to work with Delix Therapeutics, a company transforming brain health by developing treatments that are safe, fast-acting, and long-lasting. By targeting #neuroplasticity and bringing the first novel #neuroplastogen to the clinic, Delix is bringing much-needed hope to those facing difficult-to-treat #neuropsychiatric and neurological disorders. #WMHD2024 #CNS #DigitalBiomarkers #Innovation #MentalHealthMatters

Tomorrow, we stand with the global community in observing World Alzheimer's Day, a day dedicated to raising awareness and challenging the stigma surrounding #Alzheimer’s disease. With nearly 55 million people affected worldwide, it's more important than ever to support ongoing research and foster a deeper understanding of this disease as we strive for better treatments for patients and their families. At Delix, we’re harnessing the brain’s innate ability to repair and restore neurons to treat a broad range of neurological illnesses. Our innovative #neuroplastogens have the potential to revolutionize the treatment of a range of #CNS conditions, including Alzheimer's. Discover more about our innovative approach here: https://lnkd.in/dqnHGFyw

Join our CEO, Mark Rus, at TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit on Thursday, September 26. This exciting event will feature fireside chats and expert-led panel discussions exploring the latest breakthroughs in #neuropsychiatry. Don’t miss this opportunity to hear from industry leaders driving the future of neuropsychiatry!

We’re thrilled to be named a finalist for "Clinical Advancement of the Year” at the #BiotechWeekBoston BWB Awards! This recognition highlights the groundbreaking potential of emerging therapies that have successfully progressed through clinical trials and are poised to revolutionize healthcare in the near future. We are being recognized for our Proof of NonHallucinatory Platform trial where we demonstrated that our lead candidate, DLX-001, is non-hallucinogenic, non-psychotomimetic, and non-sedative, even at supratherapeutic doses. #TeamDelix is excited for an inspiring evening, celebrating the incredible achievements of all the nominees who are driving #innovation and making a lasting impact on patients’ lives!

Meet Delix Therapeutics at the 7th Annual Neuropsychiatric Drug Development Summit in Boston on September 24-26! Our CSO, Kurt Rasmussen, PhD and our CMO Aaron Koenig MD, will be speaking about Delix's groundbreaking advances of novel #neuroplastogens, #biomarkers, and #neuropsychiatry. Connect with our leadership team, including our CEO, Mark Rus, Head of Research and Development, Eliseo Salinas MD MSc, and Head of Corporate Strategy, Retsina Meyer, PhD, who will be available to discuss exciting, next-generation #innovations and future collaborations in the field.

Last Saturday, our Chief Scientific Officer, Kurt Rasmussen, Ph.D., moderated Cure Addiction Now's Fall Forum & Webinar in Los Angeles. The event brought together leading scientists, researchers, and philanthropists in the field of addiction treatment to share groundbreaking insights and innovative solutions.  Delix is proud to leverage our innovative #neuroplastogen research platform to develop treatments for #substanceusedisorders (SUDs) with the backing of a grant from The National Institute on Drug Abuse (NIDA)— part of The National Institutes of Health.  Watch the webinar here to learn more about the latest advances in SUDs: https://lnkd.in/ew9CCrJf.

Delix Therapeutics CEO, Mark Rus, recently participated in an insightful interview with Quartz’s Bruce Gil, where they discussed the FDA’s recent rejection of Lykos’s MDMA-assisted therapy for PTSD. The piece explores ongoing research and groundbreaking innovations in psychedelic therapies, emphasizing neuroplastogens' potential to address the underlying causes of many neuropsychiatric and neurodegenerative disorders without the hallucinogenic liability of traditional psychedelics. Despite the setback faced by Lykos, the future of these treatments remains promising. Check out the full article: https://lnkd.in/ewmKkVj9.

Meet Andrew Felts, PhD, Principal Scientist, Medicinal Chemistry at Delix Therapeutics! Andrew loves to contribute to the innovative research Delix is conducting in neuroplasticity and the role it plays in various #CNS disorders of enormous unmet need. We value his expertise and dedication to cutting-edge science as we continue to push boundaries to develop groundbreaking therapeutics for #neuropsychiatric conditions.